2-Amino-5-bromo-3-nitropyridine

We are 2-Amino-5-bromo-3-nitropyridine CAS:6945-68-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


Chemical Name:2-Amino-5-bromo-3-nitropyridine
CAS.NO:6945-68-2
Synonyms:2-Pyridinamine,5-bromo-3-nitro; 5-bromo-3-nitro-pyridin-2-ylamine;
5-Bromo-3-Nitro-2-Pyridinamine; 3-nitro-5-bromopyridin-2-amine;
Molecular Formula:C5H4BrN3O2
Molecular Weight:218.00800
 
Physical and Chemical Properties:
Density:1.929;
Melting point:205-208^oC;
Boiling point:302.9^oC;
Flash point:137^oC;
 
Specification:
Appearance:Yellow to light-brow
Purity:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:2-Amino-5-bromo-3-nitropyridine is an intermediate used in the preparation of azaquinoxalinedione. It is also used in the synthesis of 2,3-diaminopyridine.
 




Related News: Inceptua is a pharmaceutical company and service partner spanning throughout the product lifecycle – from comparator sourcing for clinical trials, through early access programs to licensing and commercialization for products.1,10-dibromodecano CAS:4101-68-2 “Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management,” Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said.2-hidroxi-6-cloroquinoxalina CAS:2427-71-6 “Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management,” Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said.334618-23-4 “Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management,” Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said.Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).